Cargando…

Febuxostat attenuates ER stress mediated kidney injury in a rat model of hyperuricemic nephropathy

Hyperuricemia contributes to kidney tubular injury and kidney fibrosis. However, the underlying mechanism remains unclear. Here we examined the role of RTN1A, a novel endoplasmic reticulum (ER)-associated protein and ER stress in hyperuricemic nephropathy. We first found the expression of RTN1A and...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, Li, Fan, Ying, Xiao, Wenzhen, Chen, Teng, Wen, Jiejun, Dong, Yang, Wang, Yiyun, Li, Shiqi, Xue, Rui, Zheng, Liyang, He, John Cijiang, Wang, Niansong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762322/ https://www.ncbi.nlm.nih.gov/pubmed/29340054 http://dx.doi.org/10.18632/oncotarget.22784

Ejemplares similares

Evaluation of renal microperfusion in hyperuricemic nephropathy by contrast-enhanced ultrasound imaging
por: He, Li, et al.
Publicado: (2022)

A Randomized Controlled Trial of the Effects of Febuxostat Therapy on Adipokines and Markers of Kidney Fibrosis in Asymptomatic Hyperuricemic Patients With Diabetic Nephropathy
por: Beddhu, Srinivasan, et al.
Publicado: (2016)

Rtn1a-Mediated Endoplasmic Reticulum Stress in Podocyte Injury and Diabetic Nephropathy
por: Fan, Ying, et al.
Publicado: (2017)

Astragaloside IV improves the pharmacokinetics of febuxostat in rats with hyperuricemic nephropathy by regulating urea metabolism in gut microbiota
por: Zhao, Zhen Xiong, et al.
Publicado: (2022)

Comparison of the Effects of Allopurinol and Febuxostat on the Values of Triglycerides in Hyperuricemic Patients
por: Ziga-Smajic, Nermina, et al.
Publicado: (2020)

Pharmacologic Targeting of BET Proteins Attenuates Hyperuricemic Nephropathy in Rats
por: Xiong, Chongxiang, et al.
Publicado: (2021)

Cardiovascular Safety of Febuxostat and Allopurinol in Hyperuricemic Patients With or Without Gout: A Network Meta-Analysis
por: Zhang, Shengzhao, et al.
Publicado: (2021)

Pharmacological inhibition of autophagy by 3-MA attenuates hyperuricemic nephropathy
por: Bao, Jinfang, et al.
Publicado: (2018)

Comparison of Kidney Transcriptomic Profiles of Early and Advanced Diabetic Nephropathy Reveals Potential New Mechanisms for Disease Progression
por: Fan, Ying, et al.
Publicado: (2019)

Effect of febuxostat on blood pressure in hyperuricemic patients: A protocol for a systematic review and meta-analysis
por: Yao, Jia, et al.
Publicado: (2020)

A comparative study of efficacy and safety of febuxostat and allopurinol in pyrazinamide-induced hyperuricemic tubercular patients
por: Pichholiya, Meenu, et al.
Publicado: (2016)

Ischemic Duration and Frequency Determines AKI-to-CKD Progression Monitored by Dynamic Changes of Tubular Biomarkers in IRI Mice
por: Dong, Yang, et al.
Publicado: (2019)

A Randomized, Double-Blind, Non-Inferiority Study of Febuxostat Versus Allopurinol in Hyperuricemic Chinese Subjects With or Without Gout
por: Zhang, Fengchun, et al.
Publicado: (2019)

Pharmacologic targeting ERK1/2 attenuates the development and progression of hyperuricemic nephropathy in rats
por: Liu, Na, et al.
Publicado: (2017)

Erratum. Comparison of Kidney Transcriptomic Profiles of Early and Advanced Diabetic Nephropathy Reveals Potential New Mechanisms for Disease Progression. Diabetes 2019;68:2301–2314
por: Fan, Ying, et al.
Publicado: (2020)

Efficacy of febuxostat in hyperuricemic patients with mild-to-moderate chronic kidney disease: a meta-analysis of randomized clinical trials: A PRISMA-compliant article
por: Zeng, Xiang Xia, et al.
Publicado: (2018)

Baicalein decreases uric acid and prevents hyperuricemic nephropathy in mice
por: Meng, Xiaolu, et al.
Publicado: (2017)

Endothelial injury and inflammation in patients with hyperuricemic nephropathy at chronic kidney disease stages 1-2 and 3-4
por: Xu, Li, et al.
Publicado: (2022)

Insoluble Fiber in Barley Leaf Attenuates Hyperuricemic Nephropathy by Modulating Gut Microbiota and Short-Chain Fatty Acids
por: Li, Yongmei, et al.
Publicado: (2022)

A non-inferiority study of the novel selective urate reabsorption inhibitor dotinurad versus febuxostat in hyperuricemic patients with or without gout
por: Hosoya, Tatsuo, et al.
Publicado: (2020)

Comment on “A Randomized, Double-Blind, Non-inferiority Study of Febuxostat Versus Allopurinol in Hyperuricemic Chinese Subjects with or Without Gout”
por: van Leeuwen, Kevin D. B., et al.
Publicado: (2019)

Mechanistic Insight and Management of Diabetic Nephropathy: Recent Progress and Future Perspective
por: Xue, Rui, et al.
Publicado: (2017)

RTN1 mediates progression of kidney disease by inducing ER stress
por: Fan, Ying, et al.
Publicado: (2015)

Erratum: RTN1 mediates progression of kidney disease by inducing ER stress
por: Fan, Ying, et al.
Publicado: (2015)

Evaluation the effectiveness of the Jiangniaosuan formulation in the treatment of hyperuricemic nephropathy in patients with chronic kidney disease stages 3–4: Study protocol of a randomized controlled trial
por: Lu, Lili, et al.
Publicado: (2023)

Prospective randomized comparison of effect on coronary endothelial and renal function between febuxostat and benzbromarone in hyperuricemic patients with coronary artery disease: EFEF study
por: Nishino, Masami, et al.
Publicado: (2022)

Temporal Profile of the Renal Transcriptome of HIV-1 Transgenic Mice during Disease Progression
por: Fan, Ying, et al.
Publicado: (2014)

Nef as a Proliferative Factor for Kidney Epithelial Cells in HIV-Associated Nephropathy
por: Ratnam, Krishna K., et al.
Publicado: (2008)

Integration of network pharmacology and intestinal flora to investigate the mechanism of action of Chinese herbal Cichorium intybus formula in attenuating adenine and ethambutol hydrochloride-induced hyperuricemic nephropathy in rats
por: Li, Na, et al.
Publicado: (2022)

Delayed treatment with an autophagy inhibitor 3-MA alleviates the progression of hyperuricemic nephropathy
por: Shi, Yingfeng, et al.
Publicado: (2020)

Activation of NRF2 Signaling Pathway Delays the Progression of Hyperuricemic Nephropathy by Reducing Oxidative Stress
por: Qiao, Panshuang, et al.
Publicado: (2023)

Febuxostat combined with hydration for the prevention of contrast-induced nephropathy in hyperuricemia patients undergoing percutaneous coronary intervention: A CONSORT-compliant randomized controlled trial
por: Ma, Guang, et al.
Publicado: (2022)

Anti-Hyperuricemic Effect of Anserine Based on the Gut–Kidney Axis: Integrated Analysis of Metagenomics and Metabolomics
por: Halimulati, Mairepaiti, et al.
Publicado: (2023)

Blockade of Autophagy Prevents the Progression of Hyperuricemic Nephropathy Through Inhibiting NLRP3 Inflammasome-Mediated Pyroptosis
por: Hu, Yan, et al.
Publicado: (2022)

Anti-Hyperuricemic and Nephroprotective Effects of Dihydroberberine in Potassium Oxonate- and Hypoxanthine-Induced Hyperuricemic Mice
por: Xu, Lieqiang, et al.
Publicado: (2021)

Febuxostat for the Prevention of Recurrent 2,8-dihydroxyadenine Nephropathy due to Adenine Phosphoribosyltransferase Deficiency Following Kidney Transplantation
por: Nanmoku, Koji, et al.
Publicado: (2017)

Treatment with a PPAR-γ Agonist Protects Against Hyperuricemic Nephropathy in a Rat Model
por: Wang, Xin, et al.
Publicado: (2020)

Febuxostat pretreatment attenuates myocardial ischemia/reperfusion injury via mitochondrial apoptosis
por: Wang, Shulin, et al.
Publicado: (2015)

Anti-Hyperuricemic Effect of 2-Hydroxy-4-methoxy-benzophenone-5-sulfonic Acid in Hyperuricemic Mice through XOD
por: Yong, Tianqiao, et al.
Publicado: (2018)

Crucial role of serum response factor in renal tubular epithelial cell epithelial-mesenchymal transition in hyperuricemic nephropathy
por: Zhao, Long, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_slhvkfforccj1ndg14m3a6k1ds